CMS to cover Provenge infusion costs

Dendreon Corp. (NASDAQ:DNDN) said CMS will now reimburse for infusion costs associated with prostate cancer therapy Provenge sipuleucel-T. Dendreon said the standard reimbursement for infusion-based biologics is $125 per infusion. CMS also will retroactively cover claims for infusion costs associated with the administration of Provenge on or after June 30, when CMS issued a National Coverage Determination (NCD) requiring Medicare to reimburse for the drug. Dendreon was up $0.39 to $8.73 on Monday. ...